The innovative technology also required the facility’s existing infrastructure to be upgraded and extended. WSP undertook a multidisciplinary design programme, covering everything from architecture, bio-process and equipment design to the re-engineering of the mechanical, electrical and building services. “As with the adaptation of any pre-existing facility, there are constraints on what can be achieved,” says Parker. “We did a lot of front-end masterplanning, looking at a wide variety of solutions that would help the client attain the level of throughput they desired in order to identify where that sweet spot in terms of cost balance lay.”
The success of WSP’s masterplan resulted in Astra Zeneca being better able to respond to market demand, significantly increasing the business’s resilience. The results were stark: the refreshed facility increased yields by 50% and reduced rejects by 8%, using 25% less manpower. Moreover, this boost to both quality and productivity gave the client’s R&D team greater flexibility to trial new vaccine products.
WSP’s own adaptability to unforeseen circumstances was also critical to the project. The sudden advent of the avian flu crisis presented Astra Zeneca with an important commercial opportunity. Thanks to careful masterplanning, there was enough latitude in the schedule to pause construction, allowing the client to temporarily restart production at the facility without having to extend the build programme.
We have provided the below list of services for this project:
- Feasibility and Concept design studies.
- Project management and detailed design for Civil Structural, Architectural, Specialist HVAC, Electrical, Equipment.
- Equipment validation and technical support during construction and commissioning.